Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Impaired Wnt signaling pathway plays a crucial role in the development of colorectal cancer through activation of the β-catenin/TCF7L2 complex.
|
31292489 |
2019 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
hTERT may promote CRC by recruiting β-catenin/TCF-4 complex to transactivate CCL2 expression, which is a novel crosstalk mechanism likely involved in the pathogenesis of CRC.
|
30970512 |
2019 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The CCK8 assay showed that EGFL6 promoted CRC cell growth partly by the promotion of TCF7L2 expression.
|
30693973 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
|
30529582 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer.
|
30026326 |
2018 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12.
|
29471430 |
2018 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Impaired Wnt signaling pathway plays a crucial role in the development of colorectal cancer through activation of the β-catenin/TCF7L2 complex.
|
29245969 |
2017 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated whether CRNDE was involved in the development of colorectal cancer via the binding of microRNA (miR)-217 with transcription factor 7-like 2 (TCF7L2) to enhance the Wnt signaling pathway.
|
28472810 |
2017 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
TCF7L2) that may also contribute to colorectal cancer.
|
28060743 |
2017 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that the TCF7L2 rs11196172 polymorphism increases the risk of CRC independently, with no evidence of an interaction with diabetes or obesity.
|
27792933 |
2016 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results demonstrate that patients with the T/T genotype for the rs12255372 polymorphism of the TCF7L2 gene present an increased colorectal cancer risk (OR=2.64, P=0.0236).
|
27755946 |
2016 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
To better characterize the causal relationship between β-catenin and MUCDHL expression, we performed various experiments in which CRC cell lines and normal colonic organoids were subjected to culture conditions inhibiting (FH535 treatment, transcription factor 7-like 2 siRNA inactivation, Wnt withdrawal) or stimulating (LiCl treatment) β-catenin activity.
|
27310872 |
2016 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Differential Effects of Hepatocyte Nuclear Factor 4α Isoforms on Tumor Growth and T-Cell Factor 4/AP-1 Interactions in Human Colorectal Cancer Cells.
|
26240283 |
2015 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
T-cell factor-4 (TCF4) is a member of the TCF/LEF (lymphoid enhancer factor) family of transcription factors, and dysregulation of β-catenin is decisive for the initiation and progression of colorectal cancer.
|
25961950 |
2015 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The intestine-specific transcription factor CDX2 and Wnt effector TCF7L2 bound near rs16969681, with significantly higher affinity for the risk allele, and CDX2 overexpression in CDX2/GREM1-negative cells caused re-expression of GREM1. rs16969681 influences CRC risk through effects on Wnt-driven GREM1 expression in colorectal tumors.
|
25131200 |
2014 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASDB |
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.
|
24836286 |
2014 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.
|
24836286 |
2014 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.
|
24836286 |
2014 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we have identified novel variants of VTI1A-TCF7L2 fusion transcripts, including a novel fusion partner gene, RP11-57H14.3, and demonstrated detectable levels in a large fraction of CRC samples, as well as in normal colonic mucosa and other tissue types.
|
24608966 |
2014 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
MYC and TCF7L2 were found to be activated while FOXO3 was suppressed in colorectal cancer.
|
24398765 |
2014 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphism (SNP) rs6983267 on chromosome 8q24 is a CRC susceptibility locus that affects binding activity of transcription factor 7 like-2 (TCF7L2) to CTNNB1, thereby altering expression of target oncogenes, including MYC.
|
24317174 |
2013 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR=1.17, 95%CI=1.02-1.35, I (2) =21.8%, p for heterogeneity=0.276; Heterogeneous model: OR=1.11, 95%CI=1.03-1.20, I (2) =0.0%, p for heterogeneity=0.543), prostate cancer (Homogeneous model: OR=0.89, 95%CI=0.84-0.96, I (2) =0.0%, p for heterogeneity=0.640; Heterogeneous model: OR=0.89, 95%CI=0.84-0.95, I (2) =0.0%, p for heterogeneity=0.871), and colon cancer (Heterogeneous model: OR=1.15, 95%CI=1.01-1.31, I (2) =0.0%, p for heterogeneity=0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.
|
23951231 |
2013 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results suggest that Tcf-4 is an attractive potential therapeutic target for colorectal cancer therapy.
|
23029137 |
2012 |